Get started
Author

Yungpo Bernard Su

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
2019 · Barbara Burtness, Kevin J Harrington, et al. · The Lancet · 3,328
PDF
Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm
2006 · David G. Pfister, Yungpo Bernard Su, et al. · Journal of Clinical Oncology · 295
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium
2015 · Manish A. Shah, Yelena Y. Janjigian, et al. · Journal of Clinical Oncology · 178
Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study
2023 · Neil D Gross, David M Miller, et al. · The Lancet Oncology · 102
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
2025 · Danny Rischin, Sandro Porceddu, et al. · New England Journal of Medicine · 90
Evaluation of Romidepsin for Clinical Activity and Radioactive Iodine Reuptake in Radioactive Iodine–Refractory Thyroid Carcinoma
2012 · Eric J. Sherman, Yungpo Bernard Su, et al. · Thyroid · 69
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors
2006 · Matthew G. Fury, David B. Solit, et al. · Cancer Chemotherapy and Pharmacology · 53
Immunoglobulin G4–related sclerosing disease of the paranasal sinus
2012 · Robert H. Lindau, Yungpo Bernard Su, et al. · Head & Neck · 45
Double-Blind, Placebo-Controlled, Randomized Trial of Granulocyte-Colony Stimulating Factor During Postoperative Radiotherapy for Squamous Head and Neck Cancer
2006 · Yungpo Bernard Su, Andrew J. Vickers, et al. · The Cancer Journal · 36
Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706).
2021 · Eric Jeffrey Sherman, Nathan R. Foster, et al. · Journal of Clinical Oncology · 13
A Phase I Dose-Escalation Study of Afatinib Combined with Nintedanib in Patients with Advanced Solid Tumors
2015 · Michael S Gordon, Gregory M Springett, et al. · Future Oncology · 10
Unusual Case of Papillary Thyroid Carcinoma with Choroidal Metastasis
2015 · Chhaya Makhija, Yungpo Bernard Su, et al. · Thyroid · 10
Primary intestinal‐type adenocarcinoma of the oral tongue: Case report and review of histologic origin and oncologic management
2018 · Jenna Berg, Rodolfo E. Manosalva, et al. · Head & Neck · 9
Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC).
2025 · Danny Rischin, Sandro V. Porceddu, et al. · Journal of Clinical Oncology · 4
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
2026 · Lisa Licitra, Makoto Tahara, et al. · Journal of Clinical Oncology · 3
1480 Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic HPV16-positive head and neck cancer: updated results in PD-L1 CPS ≥20 patients
2024 · Alan L Ho, Lisle Nabell, et al. · 2
Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final Analysis
2026 · Neil D. Gross, David M. Miller, et al. · Journal of Clinical Oncology
PDF
Clinical and Patient-Reported Outcomes (PROs) in C-POST: A Phase 3 Trial of Adjuvant Cemiplimab Versus Placebo for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
2025 · Danny Rischin, Chieh-I Chen, et al. · SKIN The Journal of Cutaneous Medicine
PDF
HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20.
2025 · Jong Chul Park, Lisa F. Licitra, et al. · Journal of Clinical Oncology
Residents' Work Hours
2004 · Yungpo Bernard Su, Lydia Kang · Annals of Internal Medicine
Works count: 20
Citation count: 4,248
H-index: 10
I10-index: 12
Year
Topic
Type